Disseminated Intravascular Coagulation Clinical Trial
Official title:
International Prospective Registry for the Diagnosis and Management of Disseminated Intravascular Coagulation in the Intensive Care Unit
Objectives: to evaluate the current diagnostic and therapeutic approaches for
sepis-associated disseminated intravascular coagulation (DIC) in a large prospective
registry.
Design: prospective, multicenter, international registry. Study population: patients 18 years
or older with severe infection to be potentially associated with DIC will be eligible for the
study. The clinical visits and monitoring of the patients will follow local routine
practices. No specific imaging tests or laboratory evaluations will be required and patients
will be evaluated and treated according to local policy. All the involved centers will be
asked to update information on included patients at 2, 4, 6, 8, 10 and 28 days after severe
infection diagnosis.
Study outcomes: The primary outcome of the study is the development of DIC. Secondary
outcomes are thrombotic (arterial and venous) and bleeding events, overall mortality at 28
days.
Study sample, feasibility, and analysis plan: We plan to enroll a minimum of 1000 patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04580563 -
Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study
|
N/A | |
| Completed |
NCT01704001 -
Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment
|
Phase 4 | |
| Terminated |
NCT00299949 -
Thrombin Generation and Thromboelastography in Non-overt DIC
|
N/A | |
| Withdrawn |
NCT04363840 -
The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations
|
Phase 2 | |
| Completed |
NCT04873349 -
Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients
|
N/A | |
| Withdrawn |
NCT01090115 -
Study to Look at the Effects of ART-123 on Patients With Sepsis and Disseminated Intravascular Coagulation (DIC)
|
Phase 2 | |
| Active, not recruiting |
NCT04107402 -
PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock
|
N/A | |
| Completed |
NCT00487656 -
Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation
|
Phase 2 | |
| Terminated |
NCT00506519 -
Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis
|
Phase 2 | |
| Completed |
NCT03714048 -
Blood Management During ECMO for Cardiac Support
|
||
| Completed |
NCT04547153 -
Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC
|
Phase 2 | |
| Recruiting |
NCT05995093 -
The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation
|
||
| Completed |
NCT04460664 -
Coagulation Changes Associated With COVID-19 Infection
|
||
| Completed |
NCT04356950 -
Analysis of the Coagulopathy Developed by COVID-19 Infected Patients
|
||
| Completed |
NCT04356144 -
Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections
|
||
| Recruiting |
NCT06363149 -
Disseminated Intravascular Coagulation (DIC) Score and Organ Dysfunction in Septic Shock Patients
|
||
| Recruiting |
NCT02654561 -
Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation
|
Phase 3 | |
| Active, not recruiting |
NCT06373159 -
An Observational Study to Learn About the Occurrence of Disseminated Intravascular Coagulation Among Adults With Sepsis in Japan
|
||
| Completed |
NCT03716310 -
Platelet Reactivity in Septic Shock
|